Group items tagged

Aspire Pharma has completed the acquisition of Morningside Pharmaceuticals (Loughborough), Morningside Healthcare (Leicester) and Morningside Healthcare (India); speciality generic pharmaceutical organisations. Morningside delivers Aspire added talent, increased in-market range, and an industry leading pipeline, complementary to Aspire's. "We are excited to welcome the Morningside team to the Aspire family. This is a transformative opportunity for both companies to expand and enhance our market position as a result of both companies highly complementary product portfolios. The combination will create one of the largest and fastest growing UK pharma companies and see further accelerated growth potential in our current and future product portfolio, in the UK and internationally," said Richard Condon, Chief Executive Officer of Aspire Pharma.

Rosemont Pharmaceuticals (Rosemont) has acquired Lucis Pharma Ltd, a specialist pharmaceutical business in the UK. Through this acquisition Rosemont will expand its existing portfolio and have access to a pipeline of innovative products, providing lifesaving pharmaceuticals to the UK and overseas markets. Founded in 2012, Lucis has grown to become a leading provider in the development and licensing of novel and exclusive medicines. With over a dozen SKUs covering a variety of therapeutic areas, Lucis has established a strong portfolio that, in addition to a pipeline of innovative developments, serve the growing patient need for liquid medicines. The acquisition will enable Rosemont to broaden its portfolio and enter the unit dose / sachet market through the pipeline products, whilst growing the business through recent Lucis product launches in 2021/22. "As well as continuing to broaden our portfolio and add to our strong growth globally, this acquisition also gives access to pipeline products and developer relationships to accelerate our entry into new product areas such as sachets" said Howard Taylor, Chief Executive Officer of Rosemont.

The British Generic Manufacturers Association (BGMA) has elected Diane DiGangi Trench to be its new vice-chair. DiGangi Trench takes up the position replacing Xiromed's Peter Ballard and in 12-months' time will assume the association's chair role from Accord's Peter Kelly. With over 25 years of pharmaceutical industry experience, DiGangi Trench has held a number of senior commercial roles including stints with Takeda and Astra Zeneca. She joined Sandoz in 2018 in the US, where she served as Vice-President, Market Access and Patient Services. In 2021, she became the head of Sandoz' UK business and in her two years in role, she has led the organisation through a post-COVID recovery and growth phase to prepare for the proposed spin out of the company from its parent, Novartis, expected later this year. She said: "It's a great honor to take on the role of Vice Chair of the BGMA. The success of the generics and biosimilar industry is essential to the functioning of the NHS. Generic medicines fill four out of five UK prescriptions and biosimilars enable the NHS to expand access to more patients. I am passionate about increasing the sustainability of our industry so we can continue to play our vital part in the health of the nation." Mark Samuels, BGMA chief executive, said: "We are extremely fortunate to be able to call upon the expertise of Diane who has already added significant value through her role on the BGMA board and leadership of a key strategic committee.

Despite being relatively new to the dispensing doctor market as a short-liner, Bestway Medhub is seeing exponential growth in the market in addition to the 3,500 independent pharmacies that we service and deliver to. We have however been servicing the dispensing doctor market for well over 40 years through our dispensing appliance contractor (DAC) Wardles. Wardles service and supply more than 55% of all dispensing sites with dressings, bandages, appliances, ostomy, wound care and hosiery. Graham Burford-Row To meet the needs of dispensing practices and surgeries we carry a large range of more than 10,000 Generics, PI's and OTC products. We offer net pricing so the practice can see straight away what price they are paying for their products - with no hidden fees. We offer all our practices 24-hour online ordering via our Bestway Medhub ordering portal and our recently launched Wardles FP Portal. Additionally, we have the backup of a telesales department with personal service from myself and a dedicated Internal Dispensing Dr Account Manager. We offer daily, weekly or monthly calls to those customers wishing to hear our special offers. Our deliveries are done daily via our third party full-line logistics partner for efficient deliveries, which no other short-line wholesaler offers. Bestway Medhub understands that dispensing practices are not only in the business of offering superior care to their patients and community, but they also offer numerous other services like clinics, nursing and referrals. By enabling practices to cost save, the funds could be used elsewhere instead.

The government, NHS England and the Association of the British Pharmaceutical Industry (ABPI) has begun the negotiations for a new voluntary scheme for branded medicines pricing on Thursday (4 May). A new voluntary scheme is expected to take effect from 1 January 2024, replacing the current scheme which came into force in 2019 and ends on 31 December 2023 In their first meeting, the government, NHS England and industry - represented by the ABPI -expected to agree to a shared negotiation aim of working toward a mutually beneficial agreement that supports better patient outcomes and a healthier population, a financially sustainable NHS, and UK economic growth. Health Minister, Will Quince, said: "These negotiations will ensure a new scheme continues to deliver value for money by providing significant savings for our health services, securing access to innovative lifesaving drugs for NHS patients, and helping to reduce waiting times - one of the Prime Minister's 5 priorities. The current voluntary scheme supports investment in NHS services and saves billions of pounds for the NHS, while also promoting innovations and a successful life sciences sector.

Community pharmacies were responsible for dispensing over 99 per cent of items in 2022/23, revealed General Pharmaceutical Services for Northern Ireland, Annual Statistics 2022/23 published on Thursday (29 June). While the remaining one per cent dispensed by appliance contractors and dispensing doctors. According to the statistics, on average, each community pharmacy dispensed over 84,000 items in 2022/23, witnessing a growth of over 3 per cent on the previous year to 44.6 million in 2022/23, which is the highest level of dispensing recorded. This equated to BSO processing 2.1 million prescription forms per month, on average, throughout the year, representing a 4 per cent increase on the just over 2.0m processed each month last year. The total ingredient cost over the year was £486.9 million. This was an increase of approaching 7 per cent on the previous year, which was around double the percentage increase in the number of items dispensed. The annual ingredient cost total has fluctuated since the beginning of the series but was over 18 per cent higher in 2022/23 than in 2013/14.

Pharmacy wholesaler PHOENIX UK is investing over £13 million to build a new state-of-the-art distribution hub in Wakefield. The 260,000 sq. ft facility is expected to be operational next year and will service community pharmacies, hospitals and dispensing doctors across the North East of England and Yorkshire. In a statement on Tuesday (July 5), PHOENIX UK said the completed hub will feature 22 dock level loading bays and seven access doors to enable the productive arrival and distribution of medical products. It will also be highly energy efficient, including the use of Solar PV on its roof. The car park will also offer 46 electric vehicle charging bays. Speaking at an official opening event held on 30 June to mark the expansion of the company's distribution capabilities, group managing director of PHOENIX Steve Anderson said: "Over the last few years, we have seen an outstanding growth in customer demand for our core services outpacing the market: Wakefield is a prime example of how we are committed to investing in the future by expanding our UK-wide operational capabilities to offer all our customers across the country the best possible service they need, want and deserve.

The European Union's population shrank for a second year running last year, the bloc's statistics office said on Monday, as the region reels from over two million deaths from the coronavirus. According to Eurostat, the population of the 27 countries that make up the bloc fell by close to 172,000 from the previous year and over 656,000 from January 2020. "In 2020 and 2021 the positive net migration no longer compensated for the negative natural change in the EU and, as a consequence, the EU total population has been decreasing," it said, pointing to impacts from the pandemic. The number of deaths began outstripping births in the EU a decade ago, but immigration from outside the bloc helped offset the gap until the first year of the pandemic. The previous time the EU had registered a fall in population was in 2011 - the only other time since 1960 - but this rapidly picked up due to net migration.

The Association of the British Pharmaceutical Industry (ABPI) has appointed Susan Rienow, country president of Pfizer, as its vice president. "As vice president, she will support the president, Pinder Sahota, general manager and corporate vice president of Novo Nordisk UK, in delivering his priorities. These are improving access to medicines, delivering economic growth and helping to find solutions to big societal challenges such as climate change, AMR, and inequalities," said ABPI in a statement. At Pfizer, Susan leads the organisation to bring the power of innovation, data and technology together to transform healthcare and improve outcomes for patients. She previously led Pfizer UK's vaccines business unit during the Covid-19 pandemic.

Alex Potter is the new Managing Director of PharmAssist Solutions UK, an online purchasing solution utilised by over 1,100 community pharmacies. Potter, previously the Director of Digital at Phoenix UK, will succeed the current MD, Amar Randhawa, and has expertise in the digital landscape across the industry, PharmAssist Solutions said in a statement. "We are delighted to have Alex on board," said Stuart Lucas, Chair of the PharmAssist Board. "His profound grasp of the pharmacy sector, combined with his expertise in digital innovation, will spearhead PharmAssist's evolution to meet the dynamic demands of its clientele." Meanwhile, Lucas expressed his gratitude and appreciation to Amar for his hard work and dedication over the last decade. "Amar, as the founder of PharmAssist, played a pivotal role in achieving numerous significant milestones and driving its growth," he added. "We wish him every success in his future endeavors."

Laura Wilson, Director of the Royal Pharmaceutical Society (RPS) in Scotland discussed the future of the pharmacy workforce with Michael Matheson, Cabinet Secretary for Health and Social Care at the SNP conference. The event, which took place on 17 October in Aberdeen, Scotland featured other health officials including Colin Poolman, Director of the Royal College of Nursing; Kenryck Lloyd-Jones, Public Affairs and Policy Manager for Scotland, Chartered Society of Physiotherapy; and Chris Marshall, Deputy Editor at Holyrood Communications. The Scottish government has recently unveiled its national workforce strategy for health and social care, laying out its plans for achieving recovery, growth, and transformation. Wilson highlighted the challenges and opportunities for the pharmacy workforce in Scotland to attract potential pharmacists into the profession and encourage them to stay within the profession. "This was a great opportunity to discuss with the Cabinet Secretary the challenges which exist for the pharmacy workforce in Scotland and to highlight some of the solutions which need to be implemented to ensure a pharmacy workforce in Scotland which is fit for the future," she said.

The MHRA's Criminal Enforcement Unit (CEU), working with other law enforcement partners, has seized more than two million "illegally traded medicines" this year, with a total value of £5 million. The products confiscated in the UK were prescription-only medicines including anti-depressants, pain medication and human growth hormones. The MHRA launched an initiative, Operation Pangea, 15 years ago to combat "illegal internet trade in medical" products. Andy Morling, the Deputy Director of Criminal Enforcement of MHRA, spoke about Operation Pangea's 15-year anniversary. "Fifteen years ago, the MHRA started Operation Pangea, combining our knowledge and resources with those of international partners to disrupt and bring to justice the criminal gangs responsible for selling medicines illegally and causing harm around the world.

Speaking at the SIGMA Conference 2023, Dr Leyla Hannbeck, CEO of the Association of Independent Multiple Pharmacies (AIMp), spoke about the increasing number of prescriptions, lack of funding and other existing challenges. Leyla explained how the pharmacy sector is facing immense challenges which are disrupting the delivery of services as well as impacting its growth. She further spoke about the hub and spoke model, and how it is unable to solve the issues. "Community pharmacies are clogged with prescription volume, and this is preventing them from supporting the wider NHS as well as offering services," she said. She said that the prescription volumes have rocketed, while the number of pharmacies in England has declined from 11, 522 in the year 2021-22 to 11, 414 in 2022-23. When it comes to Company Chemists' Association (CCA) pharmacies, there has been a loss of 1055 branches from 2022 to 2023.

The Department of Health and Social Care (DHSC) has published the full text of the 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG). The 2024 VPAG agreement text sets out the detailed terms of the agreement reached between DHSC, NHS England and the Association of the British Pharmaceutical Industry (ABPI) to support patient access to medicines, the financial sustainability of the NHS and the UK life sciences sector. The new voluntary scheme will come into force on 1 January 2024, following expiry of the 2019 Voluntary Scheme and shall remain in force for a period of five years, until 31 December 2028. Manufacturers or suppliers of branded medicines to the NHS have been given time till 15 January 2024 to decide whether to join the new 2024 Voluntary Scheme, or default to the updated Statutory Scheme.

The number of pharmacists working in community pharmacy in England has increased by 19 per cent in five years, according to new data released by the Department of Health and Social Care (DHSC). As of 31 October 2022, there were 27,711 community pharmacists in the country, as compared to 23,284 in 2017, an increase of almost 4,500. Pharmacy minister Andrea Leadsom revealed these figures yesterday (14 December) while responding to a written question from Karin Smyth, Shadow Minister of Health, in the parliament. Smyth asked - how many and what proportion of community pharmacists have worked in England for each of the last 10 years.

Two new subvariants of Omicron - BA.4 and BA.5 - are spreading much faster than other corovanirus variants in Europe, which could lead to more hospitalisations and deaths as they become dominant, the EU's disease prevention agency said on Monday (June 13). Most EU countries have so far detected low rates of the two subgroups. But in countries where the proportion has risen - such as Portugal, where BA.5 accounted for 87 per cent of cases by May 30 - there have been surges in overall cases, according to the European Centre for Disease Prevention and Control (ECDC). The two sublineages were added to the World Health Organization's monitoring list in March and have also been designated as variants of concern by the ECDC. Variants BA.4 and BA.5 do not appear to carry a higher risk of severe disease than other forms of Omicron.But an increase in case numbers from higher transmission rates risks leading to an increase in hospitalisations and deaths, the agency said. "The growth advantage reported for BA.4 and BA.5 suggest that these variants will become dominant," ECDC said in a statement on its website.

The Royal Pharmaceutical Society (RPS) has published a new professional guidance for prescribing practice on Monday (June 6) which it says will be "for the benefit of all independent prescribers across the UK". Based on collaboration with multi-professional stakeholders, the document is a guidance tool for prescribers wanting to expand their prescribing scope of practice. Commissioned by the Welsh government, the document was developed through an expert group with representatives from many healthcare professions, including from Higher Education institutions, professional bodies, regulatory bodies, the National Institute for Health and Care Excellence, NHS Education for Scotland, Health Education and Improvement Wales, and representatives from hospital, community and GP practice. RPS president Claire Anderson said: "It's fantastic to see the growth in prescribing, both across the profession and more widely, to improve patient care.

Health technology pioneer Invatech Health has sold its care homes electronic medication administration record (eMAR) system Atlas to care home management specialists Person Centred Software (PCS). Following the transition of Atlas to new ownership, Bristol-based Invatech Health will concentrate solely on further growth of Titan, its cutting-edge software for pharmacy management. Invatech Health CEO Tariq Muhammad, a pharmacist who started working on care homes back in 2002, first conceived the concept of electronic medicines system for care homes in 2006. Muhammad said he was proud to see his purpose-driven business given an opportunity for further progress. "It's a bit like being at a child's graduation," he said, after the completion of the acquisition which marked the end of a 20 year journey for him with Atlas. "I set up Atlas to tackle a dire need in the care homes sector for a system which could prevent incorrect dosing, mismanagement of prescriptions and administration errors of important medication.

The Health Education England (HEE) has secured funding to further support growth of the pharmacy technician workforce in 2022/23. This support is through expansion of pre-registration trainee pharmacy technician (PTPT) training capacity in community pharmacy or as part of a cross-sector integrated apprenticeship programme. HEE will be holding two 90-minute webinars on Monday 27 2022. There will be a morning webinar (10-11.30am) and an evening webinar (7-8.30pm) for attendees to choose from. Topics like- available funding; eligibility for funding; PTPT training programme requirements for employers; how to apply for this funding; and the support available from HEE for successful funding of applicants to develop their PTPT training programmes, will be covered during the webinars. HEE is also hosting another webinar to provide an update on the Independent Prescribing (IP) for pharmacists training offer that they are developing for Autumn 2022.

A group of drugs commonly used to treat erectile dysfunction may be able to boost the effect of chemotherapy in oesophageal cancer, according to new research funded by Cancer Research UK and the Medical Research Council. The research, published on Tuesday (June 22) in Cell Reports Medicine, found that the drugs, known as PDE5 inhibitors can reverse chemotherapy resistance by targeting cells called cancer-associated fibroblasts (CAFs) residing in the area surrounding the tumour. Although this is early discovery research, PDE5 inhibitors combined with chemotherapy, may be able to shrink some oesophageal tumours more than chemotherapy could alone, tackling chemotherapy resistance, which is one of the major challenges in treating oesophageal cancer. Oesophageal cancer affects the food pipe that connects the mouth to the stomach, and while it is a relatively rare cancer, the UK has one of the higher rates in the world, with 9,300 new oesophageal cancer cases in the UK every year. Resistance to chemotherapy in oesophageal cancer is influenced by the tumour microenvironment, the area that sounds the tumour. This is made up of molecules, blood vessels, and cells such as cancer associated fibroblasts (CAFs), which are important for tumour growth. It feeds the tumour and can act as a protective cloak, preventing treatments like chemotherapy from having an effect.